Funds the global Phase 3 program for KRAS G12C inhibitor elisrasib (D3S-001).
- Amount
- $108M
- Stage
- Series B
- Announced
- 10 December 2025
- Lead
- IDG Capital
- Other investors
- SongQing Capital, WuXi AppTec Corporate Venture Fund, Temasek, HSG, MPCi, Medicxi
- Use of funds
- Funds the global Phase 3 program for KRAS G12C inhibitor elisrasib (D3S-001).
- Checked
- Announced by the company